Dry Eye Syndrome Market 2034 | Industry Size, Share & Analysis
- Pallavi Garudkar
- Feb 19
- 2 min read
According to Fortune Business Insights the global dry eye syndrome market size was valued at USD 8.00 billion in 2025 and is projected to grow from USD 8.55 billion in 2026 to USD 15.09 billion by 2034, exhibiting a CAGR of 7.37% during the forecast period. Dry Eye Syndrome (DES), also known as Dry Eye Disease (DED) or Keratoconjunctivitis Sicca, is a chronic ocular condition caused by insufficient tear production or poor tear film quality. It results in irritation, redness, burning sensation, blurred vision, and ocular discomfort. The condition significantly impacts quality of life and productivity.
Get a Free Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/dry-eye-syndrome-market-102413
Market Insights
Increasing screen time due to digitalization is significantly contributing to rising dry eye cases.
Growing awareness and early diagnosis are supporting prescription drug adoption.
Expansion of OTC artificial tears and lubricants is improving accessibility.
Research and development activities are accelerating product innovation.
Telemedicine and online pharmacy growth are enhancing drug distribution.
Market Segmentation Analysis
By Product Type
Artificial Tears & Lubricants – Dominates the market due to OTC availability and high patient adoption.
Anti-inflammatory Drugs – Includes cyclosporine, corticosteroids, and immunomodulators for moderate-to-severe cases.
Other Treatment Options – Includes oral therapies, punctal plugs, and novel therapies under clinical development.
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies (Fastest-growing segment)
Others
By Disease Type
Evaporative Dry Eye
Aqueous Deficient Dry Eye
Artificial tears account for a major share owing to widespread use for mild-to-moderate conditions.
Market Dynamics
Drivers
Rising prevalence of Dry Eye Disease globally
Increasing geriatric population
Surge in digital screen exposure
Growing environmental pollution
Expanding R&D investment and drug approvals
Opportunities
Development of biologics and novel therapies
Expansion in emerging markets
Growth of online pharmacies and digital health platforms
Innovative drug delivery systems
Competitive Analysis
The Dry Eye Syndrome Market is moderately consolidated with key pharmaceutical and ophthalmology-focused companies competing based on product efficacy, pricing, regulatory approvals, and geographic presence.
Strategic initiatives include:
New product launches
Clinical trial advancements
Mergers and acquisitions
Distribution partnerships
Geographic expansion strategies
Companies are investing heavily in R&D to introduce improved formulations with enhanced patient compliance.
Key Players
AbbVie Inc. (Ireland)
Alcon (Switzerland)
Novartis AG (Switzerland)
Santen Pharmaceutical Co., Ltd. (Japan)
OASIS Medical (U.S.)
Sun Pharmaceutical Industries Ltd. (India)
Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings, Co., Ltd) (Japan)
Sentiss Pharma Pvt. Ltd. (India)
Report Coverage
This report provides:
Detailed market size analysis (2026–2034)
Forecast analysis with CAGR estimation
Segmentation by product, disease type, and distribution channel
Regional and country-level insights
Competitive landscape assessment
Key player profiling
Get Your Customization Research Report:
About Us:
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Contact Us:
Fortune Business Insights Pvt. Ltd.
9th Floor, Icon Tower,
Baner - Mahalunge Road, Baner,
Pune-411045, Maharashtra, India.
Phone:
US: +18339092966
UK: +448085020280
APAC: +91 744 740 1245 Email: sales@fortunebusinessinsights.com
Comments